Compound Activity Prediction with Dose-Dependent Transcriptomic Profiles and Deep Learning.

Journal: Journal of chemical information and modeling
Published Date:

Abstract

Predicting compound activity in assays is a long-standing challenge in drug discovery. Computational models based on compound-induced gene expression signatures from a single profiling assay have shown promise toward predicting compound activity in other, seemingly unrelated, assays. Applications of such models include predicting mechanisms-of-action (MoA) for phenotypic hits, identifying off-target activities, and identifying polypharmacologies. Here, we introduce transcriptomics-to-activity transformer (TAT) models that leverage gene expression profiles observed over compound treatment at multiple concentrations to predict the compound activity in other biochemical or cellular assays. We built TAT models based on gene expression data from a RASL-seq assay to predict the activity of 2692 compounds in 262 dose-response assays. We obtained useful models for 51% of the assays, as determined through a realistic held-out set. Prospectively, we experimentally validated the activity predictions of a TAT model in a malaria inhibition assay. With a 63% hit rate, TAT successfully identified several submicromolar malaria inhibitors. Our results thus demonstrate the potential of transcriptomic responses over compound concentration and the TAT modeling framework as a cost-efficient way to identify the bioactivities of promising compounds across many assays.

Authors

  • William J Godinez
    Novartis Institutes for BioMedical Research Inc., Basel, Switzerland.
  • Vladimir Trifonov
    Novartis Institutes for BioMedical Research, San Diego, California 92121, United States.
  • Bin Fang
    Department of Earth and Environmental Engineering, Columbia University, New York, 10027, USA.
  • Guray Kuzu
    Novartis Institutes for BioMedical Research, San Diego, California 92121, United States.
  • Luying Pei
    Novartis Institutes for BioMedical Research, Emeryville, California 94608, United States.
  • W Armand Guiguemde
    Novartis Institutes for BioMedical Research, Emeryville, California 94608, United States.
  • Eric J Martin
    Novartis Institute for Biomedical Research , 5300 Chiron Way , Emeryville , California 94608-2916 , United States.
  • Frederick J King
    Novartis Institutes for BioMedical Research, San Diego, California 92121, United States.
  • Jeremy L Jenkins
    Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States.
  • Peter Skewes-Cox
    Novartis Institutes for BioMedical Research, Emeryville, California 94608, United States.